Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SRGAP3 antisense RNA 2 is a long non-coding RNA that acts as an antisense to the SRGAP3 gene. It is involved in the regulation of gene expression and has been found to be differentially expressed in cancer samples, such as lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD), suggesting potential roles in cancer biology. Antisense RNAs like SRGAP3-AS2 can influence gene expression by interacting with their complementary mRNAs or by affecting chromatin structure and transcriptional regulation. While SRGAP3-AS2 is not typically considered a direct therapeutic target, understanding its role in modulating gene expression could provide insights into novel therapeutic strategies.
Potentially affects gene expression by interacting with regulatory elements or modulating chromatin structure
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRGAP3 antisense RNA 2 (SRGAP3-AS2).